The role of ubiquitin-proteasome system in glioma survival and growth

Growth Factors

Volumn 31, Issue 3, 2013, Pages 106-113

  Vlachostergios, Panagiotis J ^a   Voutsadakis, Ioannis A ^b   Papandreou, Christos N ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Glioma; Growth; Proliferation; Survival; Ubiquitin proteasome system

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; ACTIVATING TRANSCRIPTION FACTOR 5; BETA CATENIN; CBL PROTEIN; ELONGATION FACTOR 2 KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; HEAT SHOCK PROTEIN 70; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; NEUROFIBROMIN; NOTCH RECEPTOR; PHLPP1 PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLO LIKE KINASE 3; PROTEASOME; PROTEIN; PROTEIN P100; PROTEIN P105; PROTEIN P53; SOMATOMEDIN RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; GLIOBLASTOMA; GLIOMA CELL; GROWTH REGULATION; HUMAN; NEURAL STEM CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PYRIMIDINE METABOLISM; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; BRAIN NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; GLIOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSCRIPTION FACTORS; UBIQUITIN;

EID: 84878810188     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2013.799156     Document Type: Article

References (97)

1. Adams J. 2003. The proteasome: Structure, function, and role in the cell. Cancer Treat Rev 29:3-9. (Pubitemid 36626287)
2. Alberts GF, Winkles JA. 2004. Murine FGF-inducible kinase is rapidly degraded via the nuclear ubiquitin-proteosome system when overexpressed in NIH 3T3 cells. Cell Cycle 3:678-684. (Pubitemid 40278215)
3. Arora S, Yang JM, Hait WN. 2005. Identification of the ubiquitinproteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res 65:3806-3810. (Pubitemid 40616359)
4. Baron V, Schwartz M. 2000. Cell adhesion regulates ubiquitin-mediated degradation of the platelet-derived growth factor receptor beta. J Biol Chem 275:39318-39323. (Pubitemid 32058953)
5. Beinke S, Ley SC. 2004. Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem J 382:393-409. (Pubitemid 39243905)
6. Brognard J, Sierecki E, Gao T, Newton AC. 2007. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25:917-931. (Pubitemid 46436532)
7. Brown RE, Law A. 2006. Morphoproteomic demonstration of constitutive nuclear factor-κB activation in glioblastoma multiforme with genomic correlates and therapeutic implications. Ann Clin Lab Sci 36: 421-426. (Pubitemid 44786688)
8. Burger AM, Seth AK. 2004. The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications. Eur J Cancer 40: 2217-2229. (Pubitemid 39348871)
9. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
10. Chapman G, Liu L, Sahlgren C, Dahlqvist C, Lendahl U. 2006. High levels of Notch signaling down-regulate Numb and Numblike. J Cell Biol 175:535-540. (Pubitemid 44790606)
11. Chitra S, Nalini G, Rajasekhar G. 2012. The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases. Int J Rheum Dis 15:249-260.
12. Chondrogianni N, Gonos ES. 2012. Structure and function of the ubiquitin-proteasome system: Modulation of components. Prog Mol Biol Transl Sci 109:41-74.
13. Chuang JY, Wang YT, Yeh SH, Liu YW, Chang WC, Hung JJ. 2008. Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. Mol Biol Cell 19:1139-1151.
14. Ciechanover A, Orian A, Schwartz AL. 2000. Ubiquitin-mediated proteolysis: Biological regulation via destruction. Bioessays 22: 442-451. (Pubitemid 30308270)
15. Dahmane N, Sánchez P, Gitton Y, Palma V, Sun T, Beyna M, Weiner H, Ruiz i Altaba A. 2001. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 128: 5201-5212. (Pubitemid 34083045)
16. Dai B, Pieper RO, Li D, Wei P, Liu M, Woo SY, Aldape KD, et al. 2010. FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res 70:2951-2961.
17. Dai S, Huang ML, Hsu CY, Chao KS. 2003. Inhibition of hypoxia inducible factor 1alpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys 55:1027-1036. (Pubitemid 36287007)
18. Di K, Linskey ME, Bota DA. 2012. TRIM11 is overexpressed in highgrade gliomas and promotes proliferation, invasion, migration and glial tumor growth. Oncogene doi: 10.1038/onc.2012.531. [Epub ahead of print]
19. Di Marcotullio L, Ferretti E, Greco A, De Smaele E, Po A, Sico MA, Alimandi M, et al. 2006. Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. Nat Cell Biol 8: 1415-1423. (Pubitemid 44835117)
20. Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Mart́nez-Sáez E, Aura C, et al. 2012. USP15 stabilizes TGF-b receptor I and promotes oncogenesis through the activation of TGF-b signaling in glioblastoma. Nat Med 18:429-435.
21. Froment P, Dupont J, Christophe-Marine J. 2008. Mdm2 exerts proapoptotic activities by antagonizing insulin-like growth factor-Imediated survival. Cell Cycle 7:3098-3103.
22. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL. 2007. Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res 13:2441-2448. (Pubitemid 46698595)
23. Glasgow E, Mishra L. 2008. Transforming growth factor-beta signaling and ubiquitinators in cancer. Endocr Relat Cancer 15:59-72. (Pubitemid 351449728)
24. Glogowska A, Stetefeld J, Weber E, Ghavami S, Hoang-Vu C, Klonisch T. 2012. Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells. Neoplasia 14:396-409.
25. Goswami S, Gupta A, Sharma SK. 1998. Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem 71:1837-1845. (Pubitemid 28491538)
26. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, et al. 2004. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23:3270-3281. (Pubitemid 39209151)
27. Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G, Fukushima T. 2001. Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. Neurol Med Chir (Tokyo) 41:187-195. (Pubitemid 32416972)
28. He S, Deng J, Li G, Wang B, Cao Y, Tu Y. 2012. Down-regulation of Nedd4L is associated with the aggressive progression and worse prognosis of malignant glioma. Jpn J Clin Oncol 42:196-201.
29. Heldin CH, ten Dijke P. 1999. SMAD destruction turns off signalling. Nat Cell Biol 1:E195-197. (Pubitemid 129503658)
30. Herrmann J, Ciechanover A, Lerman LO, Lerman A. 2004. The ubiquitin-proteasome system in cardiovascular diseases-A hypothesis extended. Cardiovasc Res 61:11-21. (Pubitemid 38056676)
31. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. 1999. NF-κB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19: 2690-2698. (Pubitemid 29144513)
32. Hoeller D, Hecker CM, Dikic I. 2006. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 6:776-788. (Pubitemid 44450466)
33. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. 2003. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 115: 565-576. (Pubitemid 37506045)
34. Izaguirre DI, Zhu W, Hai T, Cheung HC, Krahe R, Cote GJ. 2012. PTBP1-dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis. Mol Carcinog 51:895-906.
35. Janssens S, Tschopp J. 2006. Signals from within: The DNA-damageinduced NF-κB response. Cell Death Differ 13:773-784.
36. Jiang W, Cazacu S, Xiang C, Zenklusen JC, Fine HA, Berens M, Armstrong B, et al. 2008. FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-κB signaling pathway. Neoplasia 10:235-243. (Pubitemid 351337518)
37. Jiang X, Xing H, Kim TM, Jung Y, Huang W, Yang HW, Song S, et al. 2012. Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and skp1-cullin-f-box ubiquitin ligase activity. Stem Cells 30:1313-1326.
38. Joy A, Moffett J, Neary K, Mordechai E, Stachowiak EK, Coons S, Rankin-Shapiro J, et al. 1997. Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells. Oncogene 14:171-183. (Pubitemid 27068303)
39. Kermorgant S, Zicha D, Parker PJ. 2003. Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J Biol Chem 278:28921-28929. (Pubitemid 36935802)
40. Kim K, Brush JM, Watson PA, Cacalano NA, Iwamoto KS, McBride WH. 2008. Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation. Mol Cancer Res 6:426-434. (Pubitemid 351416533)
41. Korkolopoulou P, Levidou G, Saetta AA, El-Habr E, Eftichiadis C, Demenagas P, Thymara I, et al. 2008. Expression of nuclear factorkappaB in human astrocytomas: Relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 39:1143-1152.
42. Krakauer T. 2008. Nuclear factor-kappaB: Fine-tuning a central integrator of diverse biologic stimuli. Int Rev Immunol 27:286-292.
43. Lennartsson J, Wardega P, Engström U, Hellman U, Heldin CH. 2006. Alix facilitates the interaction between c-Cbl and platelet-derived growth factor beta-receptor and thereby modulates receptor downregulation. J Biol Chem 281:39152-39158. (Pubitemid 46041875)
44. Li X, Liu J, Gao T. 2009a. b-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol Cell Biol 29:6192-6205.
45. Li JJ, Liu DP, Liu GT, Xie D. 2009b. EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor. Oncogene 28:1759-1768.
46. Li G, Xu Y, Guan D, Liu Z, Liu DX. 2011. HSP70 protein promotes survival of C6 and U87 glioma cells by inhibition of ATF5 degradation. J Biol Chem 286:20251-20259.
47. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, Aldape KD, et al. 2006. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66: 3593-3602.
48. Magnani M, Crinelli R, Bianchi M, Antonelli A. 2000. The ubiquitindependent proteolytic system and other potential targets for the modulation of nuclear factor-κB (NF-κB). Curr Drug Targets 1: 387-399.
49. Mani A, Gelmann EP. 2005. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23:4776-4789. (Pubitemid 46224082)
50. Mao H, Lebrun DG, Yang J, Zhu VF, Li M. 2012. Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets. Cancer Invest 30:48-56.
51. McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, et al. 2009. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16:44-54.
52. Monnier L, Milano G, Penault-Llorca F, Merlin JL. 2004. Targeting of membrane receptor tyrosine kinases: Is there resistance in the HER [Article in French] Bull Cancer 91:685-694. (Pubitemid 39382511)
53. Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T. 2002. Aberrant nuclear factor-κB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 96:909-917. (Pubitemid 34415406)
54. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. 1998. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95: 5724-5729.
55. Otsuka G, Nagaya T, Saito K, Mizuno M, Yoshida J, Seo H. 1999. Inhibition of nuclear factor-κB activation confers sensitivity to tumor necrosis factor-alpha by impairment of cell cycle progression in human glioma cells. Cancer Res 59:4446-4452. (Pubitemid 29418767)
56. Oved S, Mosesson Y, Zwang Y, Santonico E, Shtiegman K, Marmor MD, Kochupurakkal BS, et al. 2006. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J Biol Chem 281:21640-21651. (Pubitemid 44181867)
57. Platten M, Wick W, Weller M. 2001. Malignant glioma biology: Role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52:401-410. (Pubitemid 32167828)
58. Preusser M, Haberler C, Hainfellner JA. 2006. Malignant glioma: Neuropathology and neurobiology. Wien Med Wochenschr 156: 332-337. (Pubitemid 44174325)
59. Ruano Y, Mollejo M, Camacho FI, Rodŕguez de Lope A, Fiaño C, Ribalta T, Mart́nez P, et al. 2008. Identification of survival-related genes of the phosphatidylinositol 30-kinase signaling pathway in glioblastoma multiforme. Cancer 112:1575-1584. (Pubitemid 351441171)
60. Rubtsov YP, Rudensky AY. 2007. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 7:443-453. (Pubitemid 46834850)
61. Ruiz i Altaba A, Mas C, Stecca B. 2007. The Gli code: An information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 17: 438-447. (Pubitemid 47505310)
62. Ruiz i Altaba A, Palma V, Dahmane N. 2002. Hedgehog-Gli signalling and the growth of the brain. Nat Rev Neurosci 3:24-33.
63. Sallinen SL, Sallinen PK, Kononen JT, Syrjäkoski KM, Nupponen NN, Rantala IS, Helén PT, et al. 1999. Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis. J Pathol 188:289-293. (Pubitemid 29317773)
64. Sarkar FH, Li Y, Wang Z, Kong D. 2008. NF-κB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 27: 293-319.
65. Schmidt MH, Dikic I. 2006. Ubiquitin and NEDD8: Brothers in arms. Sci STKE 2006:pe50.
66. Schmidt MH, Furnari FB, Cavenee WK, Bögler O. 2003. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci USA 100:6505-6510. (Pubitemid 36666611)
67. Seton-Rogers S. 2009. Tumour suppressors: Different roads to inactivation. Nat Rev Cancer 9:610.
68. Smith D, Shimamura T, Barbera S, Bejcek BE. 2008. NF-κB controls growth of glioblastomas/astrocytomas. Mol Cell Biochem 307: 141-147.
69. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, Pieper RO. 2001. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 61: 4956-4960. (Pubitemid 32681517)
70. Stachowiak EK, Maher PA, Tucholski J, Mordechai E, Joy A, Moffett J, Coons S, Stachowiak MK. 1997. Nuclear accumulation of fibroblast growth factor receptors in human glial cells-Association with cell proliferation. Oncogene 14:2201-2211. (Pubitemid 27248232)
71. Stecca B, Ruiz i Altaba A. 2009. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J 28:663-676.
72. Stutz MA, Shattuck DL, Laederich MB, Carraway 3rd KL, Sweeney C. 2008. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 27:5741-5752.
73. Sugawa N, Ekstrand AJ, James CD, Collins VP. 1990. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602-8606.
74. Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, Lazo JS. 2009. Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol 76: 1246-1255.
75. Thomas CY, Chouinard M, Cox M, Parsons S, Stallings-Mann M, Garcia R, Jove R, Wharen R. 2003. Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. Int J Cancer 104:19-27. (Pubitemid 36184143)
76. Thompson SJ, Loftus LT, Ashley MD, Meller R. 2008. Ubiquitinproteasome system as a modulator of cell fate. Curr Opin Pharmacol 8:90-95. (Pubitemid 351168692)
77. Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD. 2007. Insulinlike growth factor type I biology and targeting in malignant gliomas. Neuroscience 145:795-811. (Pubitemid 46441671)
78. Uehara T, Matsuno J, Kaneko M, Nishiya T, Fujimuro M, Yokosawa H, Nomura Y. 1999. Transient nuclear factorκB (NF-κB) activation stimulated by interleukin-1beta may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the IkappaBalpha molecule, in C6 glioma cells. Regulation of NF-κB linked to chemokine production. J Biol Chem 274:15875-15882.
79. Walter KA, Hossain MA, Luddy C, Goel N, Reznik TE, Laterra J. 2002. Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol 22:2703-2715. (Pubitemid 34262991)
80. Warfel NA, Niederst M, Stevens MW, Brennan PM, Frame MC, Newton AC. 2011. Mislocalization of the E3 ligase, b-transducin repeatcontaining protein 1 (b-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. J Biol Chem 286: 19777-19788.
81. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N Engl J Med 359:492-507.
82. Westermark B, Heldin CH, Nistér M. 1995. Platelet-derived growth factor in human glioma. Glia 15:257-263.
83. Wu TF, Zhang W, Su ZP, Chen SS, Chen GL, Wei YX, Sun T, et al. 2012. UHRF2 mRNA expression is low in malignant glioma but silencing inhibits the growth of U251 glioma cells in vitro. Asian Pac J Cancer Prev 13:5137-5142.
84. Xu T, Zhou Q, Zhou J, Huang Y, Yan Y, Li W, Wang C, et al. 2011. Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis. Cancer Sci 102:959-966.
85. Yamamoto M, Fukushima T, Hayashi S, Ikeda K, Tsugu H, Kimura H, Soma G, Tomonaga M. 2000. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res 20:611-618. (Pubitemid 30189700)
86. Yang W, Wang L, Roehn G, Pearlstein RD, Ali-Osman F, Pan H, Goldbrunner R, et al. 2013. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. Cancer Sci 104:70-77.
87. Yang Y, Zhang C, Li L, Gao Y, Luo X, Zhang Y, Liu W, Fei Z. 2012. Up-regulated oncoprotein P28GANK correlates with proliferation and poor prognosis of human glioma. World J Surg Oncol 10:169.
88. Yeo CW, Ng FS, Chai C, Tan JM, Koh GR, Chong YK, Koh LW, et al. 2012. Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res 72:2543-2553.
89. Yokouchi M, Kondo T, Houghton A, Bartkiewicz M, Horne WC, Zhang H, Yoshimura A, Baron R. 1999. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem 274:31707-31712.
90. Yuan J, Tu Y, Mao X, He S, Wang L, Fu G, Zong J, Zhang Y. 2012. Increased expression of FAT10 is correlated with progression and prognosis of human glioma. Pathol Oncol Res 18:833-839.
91. Yue S, Chen Y, Cheng SY. 2009. Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathway. Oncogene 28:492-499.
92. Zerbini LF, Wang Y, Czibere A, Correa RG, Cho JY, Ijiri K, Wei W, et al. 2004. NF-κ B-mediated repression of growth arrest-and DNA damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci USA 101:13618-13623. (Pubitemid 39238452)
93. Zhang F, Laiho M. 2003. On and off: Proteasome and TGF-beta signaling. Exp Cell Res 291:275-281.
94. Zhang P, Lathia JD, Flavahan WA, Rich JN, Mattson MP. 2009. Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci 32:559-565.
95. Zhao Z, Tan X, Zhao A, Zhu L, Yin B, Yuan J, Qiang B, Peng X. 2012. microRNA-214-mediated UBC9 expression in glioma. BMB Rep 45: 641-646.
96. Zhou YX, Chen SS, Wu TF, Ding DD, Chen XH, Chen JM, Su ZP, et al. 2012. A novel gene RNF138 expressed in human gliomas and its function in the glioma cell line U251. Anal Cell Pathol (Amst) 35: 167-178.
97. Zuo W, Huang F, Chiang YJ, Li M, Du J, Ding Y, Zhang T, et al. 2013. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-b type II receptor. Mol Cell 49:499-510.